Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
All references in this report to ZyVersa, the Company, we, us, or our mean ZyVersa Therapeutics, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Company Overview We are a clinical stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs.
$0.10
+$0.00 (+0.00%)
Price from 3 days ago
ROIC dropped from -73.66% to -472.95%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$24M
▼ -165.1% YoY
Op. Margin
—
ROIC
-1277.14%
▼ -399.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$4M
▲ +32.0% YoY
Net Debt
-$303K
Net Cash Position
Cash & Equiv.
$303K
Continue Research
SourceComputed from the 10-Q filed 13 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 14 May 2026. How this is calculated.
Price from market data, last close as of 17 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.